智通财经APP获悉，和黄医药(00013)现涨超6%，截至发稿，涨5.23%，报25.15港元，成交额1.88亿港元。
消息面上，和黄医药公布全年业绩，收入总额6.3亿美元，同比下降24.8%；纯利3,773万美元，同比下滑62.6%。据悉，2023年1月，和黄医药与武田达成合作，交易金额达到11.3亿美元，其中首付款为4亿美元。来自这笔交易确认的收入是和黄医药2023年实现扭亏的关键因素，交易确认收入的下降也是导致和黄医药2024年营收净利双降的原因。
值得注意的是，2024年年底，和黄医药决定以6.08亿美元出售在上海和黄药业45%的股权。所得款项将用于进一步开发内部产品管线，包括公司自研抗体偶联药物(ATTC)平台。和黄医药非执行主席艾乐德表示，随着公司创新药业务逐渐走向自给自足，特别是随着公司将更多的注意力转向ATTC的全球临床开发，相信现在是时候带领和黄医药迈入下一个发展阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.